Caribou Biosciences, Inc. Increase (Decrease) in Accounts Receivable
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Accounts Receivable of $134.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$24.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $158.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$173.00K, a 313.58% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $171.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$196.00K, a 267.52% decline from fiscal 2024.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $117.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$54.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$951.00K, a 194.82% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $134.00K 10-Q · filed 2026-08-13 | -$39.00K derived: sum of 3 quarters · filed 2026-08-13 | $132.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $158.00K 10-Q · filed 2026-05-07 | -$15.00K derived: sum of 2 quarters · filed 2026-05-07 | $156.00K derived: sum of 3 quarters · filed 2026-05-07 | $139.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.00K derived: sum of 2 quarters · filed 2026-03-05 | -$19.00K derived: sum of 3 quarters · filed 2026-08-13 | -$196.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $154.00K derived: sum of 2 quarters · filed 2026-08-13 | -$23.00K 10-Q · filed 2025-11-12 | $58.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$194.00K 10-Q · filed 2026-08-13 | -$113.00K derived: sum of 3 quarters · filed 2026-08-13 | -$145.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$177.00K 10-Q · filed 2026-05-07 | -$96.00K derived: sum of 2 quarters · filed 2026-05-07 | -$128.00K derived: sum of 3 quarters · filed 2026-05-07 | -$830.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $49.00K derived: sum of 2 quarters · filed 2026-03-05 | -$653.00K derived: sum of 3 quarters · filed 2026-03-05 | $117.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$734.00K derived: sum of 2 quarters · filed 2025-11-12 | $36.00K 10-Q · filed 2025-11-12 | -$949.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$702.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $68.00K 10-Q · filed 2025-08-12 | -$917.00K derived: sum of 3 quarters · filed 2025-08-12 | -$550.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $770.00K 10-Q · filed 2025-05-08 | -$215.00K derived: sum of 2 quarters · filed 2025-05-08 | $152.00K derived: sum of 3 quarters · filed 2025-05-08 | -$615.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$618.00K derived: sum of 2 quarters · filed 2025-03-10 | -$1.39M derived: sum of 3 quarters · filed 2025-03-10 | -$54.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$400.00K derived: sum of 2 quarters · filed 2024-11-06 | $931.00K 10-Q · filed 2024-11-06 | $736.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$767.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $564.00K 10-Q · filed 2024-08-06 | $369.00K derived: sum of 3 quarters · filed 2024-08-06 | $242.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.33M 10-Q · filed 2024-05-07 | $1.14M derived: sum of 2 quarters · filed 2024-05-07 | $1.01M derived: sum of 3 quarters · filed 2024-05-07 | $1.16M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$322.00K derived: sum of 2 quarters · filed 2024-03-11 | -$172.00K derived: sum of 3 quarters · filed 2024-03-11 | -$951.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | -$127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $23.00K derived: sum of 2 quarters · filed 2023-11-07 | -$756.00K 10-Q · filed 2023-11-07 | -$181.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$629.00K 10-Q · filed 2023-08-08 | -$54.00K derived: sum of 3 quarters · filed 2023-08-08 | $522.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$779.00K 10-Q · filed 2023-05-09 | -$204.00K derived: sum of 2 quarters · filed 2023-05-09 | $372.00K derived: sum of 3 quarters · filed 2023-05-09 | $298.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.15M derived: sum of 2 quarters · filed 2023-03-09 | $1.08M derived: sum of 3 quarters · filed 2023-03-09 | $1.00M 10-K · filed 2023-03-09 |
| 2021-09-30 | $576.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $502.00K derived: sum of 2 quarters · filed 2022-11-08 | $428.00K 10-Q · filed 2022-11-08 | $578.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$148.00K 10-Q · filed 2022-08-09 | $2.00K derived: sum of 3 quarters · filed 2022-08-09 | -$19.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$74.00K 10-Q · filed 2022-05-09 | $76.00K derived: sum of 2 quarters · filed 2022-05-09 | $55.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $129.00K derived: sum of 2 quarters · filed 2022-03-21 | $146.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$4.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $17.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | -$617.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |